283 related articles for article (PubMed ID: 18552124)
1. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor.
Redka DS; Pisterzi LF; Wells JW
Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124
[TBL] [Abstract][Full Text] [Related]
2. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
[TBL] [Abstract][Full Text] [Related]
3. Two-state models and the analysis of the allosteric effect of gallamine at the M2 muscarinic receptor.
Ehlert FJ; Griffin MT
J Pharmacol Exp Ther; 2008 Jun; 325(3):1039-60. PubMed ID: 18305010
[TBL] [Abstract][Full Text] [Related]
4. Recovery of oligomers and cooperativity when monomers of the M2 muscarinic cholinergic receptor are reconstituted into phospholipid vesicles.
Ma AW; Redka DS; Pisterzi LF; Angers S; Wells JW
Biochemistry; 2007 Jul; 46(26):7907-27. PubMed ID: 17552496
[TBL] [Abstract][Full Text] [Related]
5. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors.
Tränkle C; Weyand O; Voigtländer U; Mynett A; Lazareno S; Birdsall NJ; Mohr K
Mol Pharmacol; 2003 Jul; 64(1):180-90. PubMed ID: 12815174
[TBL] [Abstract][Full Text] [Related]
6. Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
Grossmüller M; Antony J; Tränkle C; Holzgrabe U; Mohr K
Naunyn Schmiedebergs Arch Pharmacol; 2006 Jan; 372(4):267-76. PubMed ID: 16362429
[TBL] [Abstract][Full Text] [Related]
7. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
[TBL] [Abstract][Full Text] [Related]
8. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
May LT; Lin Y; Sexton PM; Christopoulos A
J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
[TBL] [Abstract][Full Text] [Related]
9. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry.
Whitehurst CE; Nazef N; Annis DA; Hou Y; Murphy DM; Spacciapoli P; Yao Z; Ziebell MR; Cheng CC; Shipps GW; Felsch JS; Lau D; Nash HM
J Biomol Screen; 2006 Mar; 11(2):194-207. PubMed ID: 16490772
[TBL] [Abstract][Full Text] [Related]
11. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
[TBL] [Abstract][Full Text] [Related]
12. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor.
Leppik RA; Miller RC; Eck M; Paquet JL
Mol Pharmacol; 1994 May; 45(5):983-90. PubMed ID: 8190113
[TBL] [Abstract][Full Text] [Related]
13. Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors.
Lanzafame A; Christopoulos A; Mitchelson F
J Pharmacol Exp Ther; 1997 Jul; 282(1):278-85. PubMed ID: 9223565
[TBL] [Abstract][Full Text] [Related]
14. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
Lanzafame AA; Sexton PM; Christopoulos A
Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
[TBL] [Abstract][Full Text] [Related]
15. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
[TBL] [Abstract][Full Text] [Related]
16. Two allosteric modulators interact at a common site on cardiac muscarinic receptors.
Ellis J; Seidenberg M
Mol Pharmacol; 1992 Oct; 42(4):638-41. PubMed ID: 1435741
[TBL] [Abstract][Full Text] [Related]
17. Using a radioalloster to test predictions of the cooperativity model for gallamine binding to the allosteric site of muscarinic acetylcholine M(2) receptors.
Tränkle C; Weyand O; Schröter A; Mohr K
Mol Pharmacol; 1999 Nov; 56(5):962-5. PubMed ID: 10531401
[TBL] [Abstract][Full Text] [Related]
18. Competition between positive and negative allosteric effectors on muscarinic receptors.
Proska J; Tucek S
Mol Pharmacol; 1995 Oct; 48(4):696-702. PubMed ID: 7476896
[TBL] [Abstract][Full Text] [Related]
19. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.
Matsui H; Lazareno S; Birdsall NJ
Mol Pharmacol; 1995 Jan; 47(1):88-98. PubMed ID: 7838137
[TBL] [Abstract][Full Text] [Related]
20. Monomers and oligomers of the M2 muscarinic cholinergic receptor purified from Sf9 cells.
Park PS; Wells JW
Biochemistry; 2003 Nov; 42(44):12960-71. PubMed ID: 14596611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
